A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma

Cancer Gene Therapy

Volumn 10, Issue 3, 2003, Pages 179-186

  Yamamoto, Seiji ^a,b   Yamano, Tomoki ^a,c   Tanaka, Maki ^c   Hoon, Dave S B ^c   Takao, Sonshin ^b   Morishita, Ryuichi ^a   Aikou, Takashi ^b   Kaneda, Yasufumi ^a,d  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Histone deacetylase inhibitor; Melanoma; Nonviral gene delivery; Suicide gene therapy

Indexed keywords

FR 901229; GANCICLOVIR; HISTONE DEACETYLASE INHIBITOR; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GENE THERAPY; HERPES SIMPLEX VIRUS; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE THERAPY; SURVIVAL; TIME; TRANSGENE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BETA-GALACTOSIDASE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DEPSIPEPTIDES; ENZYME INHIBITORS; GANCICLOVIR; GENE EXPRESSION; GENE THERAPY; HISTONE DEACETYLASES; INJECTIONS, INTRALESIONAL; LIPOSOMES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PEPTIDES, CYCLIC; THYMIDINE KINASE;

ANIMALIA; SIMPLEXVIRUS;

EID: 0037345704     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700551     Document Type: Article

References (40)

1. Marshall E. Gene therapy's growing pains. Science. 1995;269:1052-1055.
2. Mulligan RC. The basic science of gene therapy. Science. 1993;260:926-932.
3. Palmer TD, Rosman GJ, Osborne WR, et al. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA. 1991;88:1330-1334.
4. Harbers K, Jahner D, Jaenisch R. Microinjection of cloned retroviral genomes into mouse zygotes: integration and expression in the animal. Nature. 1981;293:540-542.
5. Jahner D, Stuhlmann H, Stewart CL, et al. De novo methylation and expression of retroviral genomes during mouse embryogenesis. Nature. 1982;298:623-628.
6. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet. 1994;6:335-341.
7. Roeder RG. The role of general transcription factors in transcription by polymerase II. Trends Biochem Sci USA. 1996;21:327-335.
8. Grunstein M. Histone acetylation and chromatin structure and transcription. Nature. 1997;389:349-352.
9. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin:novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays. 1995;17:423-430.
10. Riggs MG, Whittaker RG, Neumann JR, et al. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature. 1997;268:462-464.
11. Chen WY, Bailey EC, McCune SL, et al. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci USA. 1997;94:5798-5803.
12. Dion LD, Goldsmith KT, Tang DC, et al. Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Virology. 1997;231:201-209.
13. Nakajima H, Kim YB, Terano H, et al. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 1998;241:126-133.
14. Yamano T, Ura K, Morishita R, et al. Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. Molecular Ther. 2000;1:425-431.
15. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Nail Cancer Inst. 2000;92:1210-1216.
16. Oldfield EH, Ram Z, Culver KW, et al. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous gancyclovir. Hum Gene Ther. 1993;4:39-69.
17. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274-5283.
18. Mullen CA, Coale MM, Lowe R, et al. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 1994;54:!QJ;1503-1506.
19. Kaneda Y, Saeki Y, Morishita R. Gene therapy using HVJ-liposomes;the best of both worlds. Mol Med Today. 1999;5:298-303.
20. Saeki Y, Matsumoto N, Nakano Y, et al. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus); reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther. 1997;8:2133-2142.
21. Chan KC, Bakhtiar R, Jiang C. Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat but LC/MS/MS. Invest New Drug. 1997;15:195-206.
22. Dethlefsen LA, Prewitt JM, Mendelsohn ML. Analysis of tumor growth curves. J Natl Cancer Inst. 1968;40:389-405.
23. Wolffe AP, Pruss D. Targeting chromatin disruption: transcription regulators that acerylate histones. Cell. 1996;84:817-819.
24. Imhof A, Yang XJ, Ogryzko VV, et al. Acetylation of general transcription factors by histone acetyltransferase. CurrBiol. 1997;7:689-692.
25. Pazin MJ, Kadonaga JT. What's up and down with histone deacetylation and transcription? Cell. 1997;89:325-328.
26. Doetzlhofer A, Rotheneder H, Lagger G, et al. Histone deacetylase 1 can repress transcription by binding to Spl. Mol Cell Biol. 1999;19:5504-5511.
27. Xiao H, Hasegawa T, Isobe KI. Both Spl and Sp3 are responsible for p21 wafl promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem. 1999;73:291-302.
28. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997;90:595-606.
29. Imhof A, Yang XJ, Ogryzko VV, et al. Acetylation of general transcription factors by histone acetyltransferases. Curr Biol. 1997;7:689-692.
30. Boyes J, Byfield P, Nakatani Y, et al. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature. 1998;396:594-598.
31. Zhang W, Bieker JJ. Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc Natl Acad Sci USA. 1998;95:9855-9860.
32. Sandor V, Senderowicz A, Mertins S, et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. BrJ Cancer. 2000;83:817-825.
33. Rajgolikar G, Chan KK, Wang HC. Effect of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast cancer Res Treat. 1998;51:29-38.
34. Ueda H, Manda T, Matsumoto S, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo). 1994;47:315-323.
35. Ueda H, Nakajima H, Hori Y, et al. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem. 1994;58:1579-1583.
36. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory Neoplasms. Clin Cancer Res. 2002;8:718-728.
37. Hirano T, Fujimoto J, Ueki T, et al. Persistent gene expression in rat liver in vivo by repetitive transfections using HVJ-liposome. Gene Ther. 1998;4:459-464.
38. Otomo T, Yamamoto S, Morishita R, et al. EBV replicon vector system enhances transgene expression in vivo: applications to cancer gene therapy. J Gene Med. 2001;3:345-352.
39. Maeda T, Towatari M, Kosugi H, et al. Up-regulation of costimulator/adhesion molecules by histone deacerylase inhibitors in acute myeloid leukemia cells. Blood. 2000;96:3847-3856.
40. Todd SW, Galen AO, Zong SG, et al. Induction of Mage-3 expression in lung and esophageal cancer cells. Ann Thorac Surg. 2001;71:295-302.